Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 201–300 of 1,012
Prioritizing targets for precision cancer medicine
Andre, F., Mardis, E., Salm, M., Soria, J.-C., Siu, L. L., & Swanton, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu478 · Cited by 164
“As illustration, B-RAF V600E mutations define sensitivity to vemurafenib in melanoma or to dabrafenib in NSCLC [46].”
BackgroundArvelo, F. A., Sojo, F., & Cotte, C. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.520 · Cited by 201
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Systems biology approaches for advancing the discovery of effective drug combinations
Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 159
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160
“…other reported mechanisms of resistance to inhibitors of the RTK/Ras/MAPK pathway (Rudin et al., 2013; Wagle et al., 2011; Corcoran et al., 2012; Prahallad et al., 2012; Sun et al., 2014; Johannessen et al., 2010; Nazarian et al., 2010), we found that KEAP1KO did not restore ERK activation…”
BackgroundCancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.001 · Cited by 146
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
Designing Transformative Clinical Trials in the Cancer Genome Era
Sleijfer, S., Bogaerts, J., & Siu, L. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3639 · Cited by 156
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Self-citationClancy, C., Burke, J. P., Kalady, M. F., & Coffey, J. C. (2013) · Colorectal Disease · doi:10.1111/codi.12427 · Cited by 133
Network quantification of EGFR signaling unveils potential for targeted combination therapy
Klinger, B., Sieber, A., Fritsche‐Guenther, R., Witzel, F., Berry, L., Schumacher, D., Yan, Y., Durek, P., Merchant, M., Schäfer, R., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.29 · Cited by 155
Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer
Sullivan, B. A., Noujaim, M. G., & Roper, J. (2022) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2021.12.001 · Cited by 179
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 168
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Trial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zucman-Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 149
Molecular Diagnostics in Clinical Oncology
Соколенко, А. П., & Имянитов, Е. Н. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00076 · Cited by 172
Clinical relevance of colorectal cancer molecular subtypes
Rodríguez-Salas, N., Dominguez, G., Barderas, R., Mendiola, M., García‐Albéniz, X., Maurel, J., & Batlle, J. F. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.007 · Cited by 171
Normanno, N., Rachiglio, A. M., Lambiase, M., Martinelli, E., Fenizia, F., Esposito, C., Roma, C., Troiani, T., Rizzi, D., Tatangelo, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv176 · Cited by 157
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
Schreck, K. C., Grossman, S. A., & Pratilas, C. A. (2019) · Cancers · doi:10.3390/cancers11091262 · Cited by 147
The nuclear translocation of ERK1/2 as an anticancer target
Plotnikov, A., Flores, K., Maik-Rachline, G., Zehorai, E., Kapri-Pardes, E., Berti, D. A., Hanoch, T., Besser, M. J., & Seger, R. (2015) · Nature Communications · doi:10.1038/ncomms7685 · Cited by 142
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Sanchez, J., Wang, T., & Cohen, M. S. (2018) · Drugs · doi:10.1007/s40265-018-0884-8 · Cited by 155
Ponsioen, B., Post, J. B., Amorie, J. R. B. D., Laskaris, D., van Ineveld, R. L., Kersten, S., Bertotti, A., Sassi, F. P., Sipieter, F., Cappe, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00654-5 · Cited by 164
Morkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144
Clinical and Radiographic Response With Combined BRAF-Targeted Therapy in Stage 4 Ameloblastoma
Kaye, F. J., Ivey, A. M., Drane, W. E., Mendenhall, W. M., & Allan, R. W. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju378 · Cited by 146
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Akhavan, D., Pourzia, A. L., Nourian, A. A., Williams, K. J., Nathanson, D. A., Babić, I., Villa, G. R., Tanaka, K., Nael, A., Yang, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0502 · Cited by 161
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Kopetz, S., Yoshino, T., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03443-3 · Cited by 124
Tumor heterogeneity in the clinic: is it a real problem?
Jankú, F. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013517414 · Cited by 161
Participation of the Elderly Population in Clinical Trials: Barriers and Solutions
Denson, A. C., & Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100305 · Cited by 138
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Fabbro, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095489 · Cited by 152
Irmisch, A., Bonilla, X., Chevrier, S., Lehmann, K.-V., Singer, F., Toussaint, N. C., Esposito, C., Mena, J., Milani, E. S., Casanova, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.004 · Cited by 149
Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
Antoun, N. B., & Chioni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512222 · Cited by 152
He, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 160
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
Weigelt, B., Warne, P. H., Lambros, M. B. K., Reis-Filho, J. S., & Downward, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3815 · Cited by 148
Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK
Tolcher, A. W., Khan, K., Ong, M., Banerji, U., Papadimitrakopoulou, V., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 137
Molecular‐targeted agents combination therapy for cancer: Developments and potentials
Li, F., Zhao, C., & Wang, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28261 · Cited by 160
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
BRAF Mutation in Colorectal Cancer: An Update: Supplementary Issue: Biomarkers for Colon Cancer
Barras, D. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25248 · Cited by 138
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 150
Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 153
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers
Tokheim, C., & Karchin, R. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.005 · Cited by 124
Functional characterization of a PROTAC directed against BRAF mutant V600E
Posternak, G., Tang, X., Maisonneuve, P., Jin, T., Lavoie, H., Daou, S., Orlicky, S., Goullet de Rugy, T., Caldwell, L., Chan, K., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0609-7 · Cited by 127
Chylek, L. A., Harris, L. A., Tung, C., Faeder, J. R., Lopez, C. F., & Hlavacek, W. S. (2014) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1245 · Cited by 131
Herrera-Abreu, M. T., Pearson, A., Campbell, J., Shnyder, S. D., Knowles, M. A., Ashworth, A., & Turner, N. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0569 · Cited by 128
Defining actionable mutations for oncology therapeutic development
Carr, T. H., McEwen, R. K., Dougherty, B. A., Johnson, J. H., Dry, J. R., Lai, Z., Ghazoui, Z. F., Laing, N. M., Hodgson, D., Cruzalegui, F. H., et al. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.35 · Cited by 143
Gay, L., Baker, A.-M., & Graham, T. A. (2016) · F1000Research · doi:10.12688/f1000research.7210.1 · Cited by 125
Picco, G., Chen, E. D., García‐Alonso, L., Behan, F. M., Gonçalves, E., Bignell, G. R., Matchan, A., Fu, B., Banerjee, R., Anderson, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09940-1 · Cited by 139
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Roviello, G., D’Angelo, A., Petrioli, R., Roviello, F., Cianchi, F., Nobili, S., Mini, E., & Lavacchi, D. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100795 · Cited by 131
Clinical Analysis and Interpretation of Cancer Genome Data
Van Allen, E. M., Wagle, N., & Levy, M. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7215 · Cited by 126
Targeted therapies for gastric cancer: failures and hopes from clinical trials
Apicella, M., Corso, S., & Giordano, S. (2017) · Oncotarget · doi:10.18632/oncotarget.14825 · Cited by 135
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
Heinemann, V., Douillard, J. Y., Ducreux, M., & Peeters, M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.011 · Cited by 120
Vizoso, M., Ferreira, H. J., López-Serra, P., Carmona, F. J., Martínez‐Cardús, A., Girotti, M. R., Villanueva, A., Guil, S., Moutinho, C., Liz, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3863 · Cited by 133
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Xue, Z., Vis, D. J., Bruna, A., Sustic, T., van Wageningen, S., Batra, A. S., Rueda, O. M., Bosdriesz, E., Caldas, C., Wessels, L. F. A., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0044-4 · Cited by 125
Self-citationSforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Roesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 139
Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 121
Mechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P., Blackhall, F., & Lindsay, C. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 117
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover
Hong, X., Nguyen, H. T., Chen, Q., Zhang, R., Hagman, Z., Voorhoeve, P. M., & Cohen, S. M. (2014) · The EMBO Journal · doi:10.15252/embj.201489385 · Cited by 121
“PI3K can serve as an effector of activated K-Ras in pancreatic cancer cells (Prahallad et al , 2012; Eser et al , 2013) and K-Ras activity can modulate EGFR activation in colorectal cancer cells (Prahallad et al , 2012).”
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Self-citationImportant molecular genetic markers of colorectal cancer
Kudryavtseva, A. V., Lipatova, A. V., Zaretsky, A. R., Moskalev, A. A., Fedorova, M. S., Rasskazova, A. S., Shibukhova, G. A., Snezhkina, A. V., Kaprin, A. D., Alekseev, B. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9796 · Cited by 114
Xue, Y., Meehan, B., Macdonald, E. A., Venneti, S., Wang, X. Q. D., Witkowski, L., Jelinic, P., Kong, T., Martínez, D., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-06958-9 · Cited by 128
Self-citationOhta, A., Tanada, M., Shinohara, S., Morita, Y., Nakano, K., Yamagishi, Y., Takano, R., Kariyuki, S., Iida, T., Matsuo, A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07145 · Cited by 121
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
“They are mainly used in the treatment of melanoma, but the efficacy of single-agent therapy for mCRCs remains unclear [68], which is mainly related to the fact that, after inhibiting the MAPK pathway using BRAF inhibitors, EGFR can be activated by feedback in mCRCs, whereas melanoma only expresses low-level EGFR [69,…”
BackgroundUpdates of reactive oxygen species in melanoma etiology and progression
Liu-Smith, F., Dellinger, R., & Meyskens, F. L. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.04.007 · Cited by 115
Gouda, M. A., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100788 · Cited by 127
Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential
Wang, C., Zhang, Y., Guo, K., Wang, N., Jin, H., Liu, Y., & Qin, W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29723 · Cited by 120
A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
Guo, G., Gong, K., Ali, S., Ali, N., Shallwani, S., Hatanpaa, K. J., Pan, E., Mickey, B., Burma, S., Wang, D. H., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4584 · Cited by 113
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O’Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 107
Evolving Approaches to Patients with Advanced Differentiated Thyroid Cancer
Haugen, B. R., & Sherman, S. I. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1038 · Cited by 124
Li, Q., Zhang, D., Chen, X., He, L., Li, T., Xu, X., & Li, M. (2015) · Scientific Reports · doi:10.1038/srep16082 · Cited by 114
“Recent clinical reports, however, have disappointingly shown that, even though gefitinib has indicated some anti-tumor action against CRC, a high level of novel resistance has occurred in response to such treatment 3,4 .”
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z., Chakraborty, A., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M. W., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 112
Hoefflin, R., Geißler, A.-L., Fritsch, R., Claus, R., Wehrle, J., Metzger, P., Reiser, M., Mehmed, L., Fauth, L., Heiland, D. H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00105 · Cited by 124
Picco, G., Cattaneo, C. M., van Vliet, E. J., Crisafulli, G., Rospo, G., Consonni, S., Vieira, S. F., Sánchez-Rodríguez, I., Cancelliere, C., Banerjee, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1508 · Cited by 123
Self-citationBRAF inhibitors in cancer therapy
Johansson, C. H., & Brage, S. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.011 · Cited by 122
Oikonomou, E., Koustas, E., Goulielmaki, M., & Pintzas, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2555 · Cited by 133
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 119
Pandyra, A. A., Mullen, P., Kalkat, M., Yu, R., Pong, J. T., Li, Z., Trudel, S., Lang, K. S., Minden, M. D., Schimmer, A. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0130 · Cited by 121
Wu, X., He, C., Wu, Y., Chen, X., & Cheng, J. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201502742 · Cited by 115
Mechanisms shaping the role of ERK1/2 in cellular sene scence (Review)
Zou, J., Lei, T., Guo, P., Yu, J., Xu, Q., Luo, Y., Ke, R., & Huang, D. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9712 · Cited by 136
Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 110
Elez, E., Ros, J., Fernández, J., Villacampa, G., Moreno-Cárdenas, A. B., Arenillas, C., Bernatowicz, K., Comas, R., Li, S., Kodack, D. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01976-z · Cited by 111
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
Crispo, F., Notarangelo, T., Pietrafesa, M., Lettini, G., Storto, G., Sgambato, A., Maddalena, F., & Landriscina, M. (2019) · Cancers · doi:10.3390/cancers11091388 · Cited by 113
Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology
Hristova‐Panusheva, K., Xenodochidis, C., Georgieva, M., & Krasteva, N. A. (2024) · Pharmaceuticals · doi:10.3390/ph17060677 · Cited by 132
Molecular Dissection of Microsatellite Instable Colorectal Cancer
Vilar, E., & Tabernero, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0471 · Cited by 111
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
“In line with this observation, the combination of BRAF and EGFR inhibitors has been proved to be effective in BRAFV600E colon cancer patients [8,9].”
ResultSelf-citationThe heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
Fanelli, G. N., Pozzo, C. A. D., Depetris, I., Schirripa, M., Brignola, S., Biason, P., Balistreri, M., Santo, L. D., Lonardi, S., Munari, G., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1117-2 · Cited by 129
Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis
Wu, W. K. K., Wang, X., Cheng, A. S. L., Luo, M. X. M., Ng, S. S. M., To, K. F., Chan, F. K. L., Cho, C. H., Sung, J. J. �., & Yu, J. Q. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.009 · Cited by 115
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 129
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 110
Self-citationEfficient synthesis of phycocyanobilin in mammalian cells for optogenetic control of cell signaling
Uda, Y., Goto, Y., Oda, S., Kohchi, T., Matsuda, M., & Aoki, K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707190114 · Cited by 124
Li, Z.-N., Zhao, L., Yu, L.-F., & Wei, M.-J. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa022 · Cited by 104
Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention
Zhang, L., & Yu, J. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0188-z · Cited by 124
“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 105
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
Berns, K., Caumanns, J. J., Hijmans, E. M., Gennissen, A. M. C., Severson, T., Evers, B., Wisman, G. B. A., Meersma, G. J., Lieftink, C., Beijersbergen, R. L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0300-6 · Cited by 110
Self-citationVojnic, M., Kubota, D., Kurzatkowski, C., Offin, M., Suzawa, K., Benayed, R., Schoenfeld, A. J., Plodkowski, A. J., Poirier, J. T., Rudin, C. M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.038 · Cited by 104
Uitdehaag, J. C. M., de Roos, J. A. D. M., van Doornmalen, A. M., Prinsen, M. B. W., de Man, J., Tanizawa, Y., Kawase, Y., Yoshino, K., Buijsman, R. C., & Zaman, G. J. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092146 · Cited by 116
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.